**Supplementary Table 5. Adverse events over the 24-month study period.**

|  |  |  |
| --- | --- | --- |
| **Number (%) of patients with** | **BRVO**  N=226 | **CRVO**  N=196 |
| At least 1 AE, | 108 (47.8%) | 102 (52.0%) |
| At least 1 AE related to ranibizumab or intravitreal injection | 43 (19.0%) | 28 (14.3%) |
| At least 1 AE related to ranibizumab | 22 (9.7%) | 11 (5.6%) |
| At least 1 SAE related to ranibizumab | 5 (2.2%) | 2 (1.0%) |
| Most common AEs | Ocular hypertension (5.8%)  Retinal ischemia (5.8%)  Ocular pain (4.4%) Aggravated infection (4.4%)  Ineffective drug (3.5%)  Vitreal floating bodies (3.1%)  Ocular irritation (3.1%)  Conjunctival bleeding (2.7%) Fall (2.2%) | Ocular pain (6.6%)  Ocular hypertension (5.1%)  Retinal ischemia (4.6%) Aggravated infection (4.6%) Ineffective drug (3.6%) Glaucoma (3.6%) Ocular pruritis (3.1%)  Cataract (2.6%) Iris neovascularization (2.6%)  Drop in VA (2.0%) Macular ischemia (2.0%) Macular edema (2.0%) Cardiac insufficiency (2.0%) Fall (2.0%) |

AE=adverse event, BRVO=branch retinal vein occlusion, CRVO=central retinal vein occlusion, SAE=serious adverse event, VA=visual acuity